"It really expands the bandwidth of our data scientists to apply materials informatics to our data." At an Intellegens webinar, Dr Josh Stuckner from NASA Glenn Research Center presented work to test and validate the Alchemite machine learning method. NASA had applied the tool to two projects: design of heat exchangers and shape memory alloys. In both cases, Alchemite was compared to alternative machine learning approaches -- the presentation focused on comparisons with the Random Forest method. Alchemite predictions based on complete datasets from the two applications were found to compare well with those from the other methods.

Cambridge startup Intellegens has secured a landmark maiden deal for its Alchemite artificial intelligence technology. The company has revealed its first commercial collaboration – with e-Therapeutics, an Oxford-based pioneer of Network-Driven Drug Discovery. Alchemite will enable e-Therapeutics to generate improved predictions, correct errors and fill in gaps in the large-scale biological and chemical information repositories housed in the company's proprietary databases. Alchemite is the result of intensive research by Dr Gareth Conduit, CTO and Intellegens co- founder. Working at the world-famous Cavendish Laboratories in Cambridge, Dr Conduit discovered a new method of analysing sparsely populated matrices using deep neural networks and novel machine learning approaches.